Clinical utility of eslicarbazepine: current evidence

Clinical utility of eslicarbazepine: current evidence

Gaetano Zaccara,1 Fabio Giovannelli,1,2 Massimo Cincotta,1 Alessia Carelli,3 Alberto Verrotti31Department of Medicine, Unit of Neurology, Florence Health Authority, Florence, Italy; 2Department of Neuroscience, Psychology, Pharmacology and Child Health (NEUROFARBA), University of F...

Full description

Bibliographic Details
Main Authors:	Zaccara G, Giovannelli F, Cincotta M, Carelli A, Verrotti A
Format:	Article
Language:	English
Published:	Dove Medical Press 2015-02-01
Series:	Drug Design, Development and Therapy
Online Access:	http://www.dovepress.com/clinical-utility-of-eslicarbazepine-current-evidence-peer-reviewed-article-DDDT

Similar Items

Eslicarbazepine acetate as therapy in hemifacial spasm
by: M. Marín Gracia, et al.
Published: (2022-04-01)

Eslicarbazepine acetate for neuropathic pain, headache, and cranial neuralgia: evidence and experience
by: A. Alcántara Montero, et al.
Published: (2019-07-01)

Healthcare Resource Utilization Pre- and Post-Initiation of Eslicarbazepine Acetate Among Pediatric Patients with Focal Seizure: Evidence from Routine Clinical Practice
by: Mehta D, et al.
Published: (2020-07-01)

Eslicarbazepine acetate: An efficacy and safety as an antiepileptic drug in clinical trials and open studies
by: Martyna Stefaniak, et al.
Published: (2022-02-01)

Eslicarbazepine‐induced hyponatremia: A retrospective single‐center real clinical practice study
by: Ondřej Strýček, et al.
Published: (2024-02-01)

Dibenzazepine Agents in Epilepsy: How Does Eslicarbazepine Acetate Differ?
by: Charlotte Lawthom, et al.
Published: (2018-09-01)

EPICON consensus: Recommendations for proper management of switching to eslicarbazepine acetate in epilepsy
by: V. Villanueva, et al.
Published: (2018-06-01)

Post-authorisation study of eslicarbazepine as treatment for drug-resistant epilepsy: preliminary results
by: A. Massot, et al.
Published: (2014-03-01)

Eslicarbazepine Induced Stevens-Johnson Syndrome: A Rare Case Report
by: Kamal Nath, et al.
Published: (2018-06-01)

Inhibitory Effect of Eslicarbazepine Acetate and S-Licarbazepine on Nav1.5 Channels
by: Theresa K. Leslie, et al.
Published: (2020-10-01)

Role of eslicarbazepine in the treatment of epilepsy in adult patients with partial-onset seizures
by: Martin E Brown, et al.
Published: (2010-03-01)

A Review of Eslicarbazepine Acetate for the Adjunctive Treatment of Partial-Onset Epilepsy
by: Rajinder P. Singh, et al.
Published: (2011-01-01)

Eslicarbazepine acetate: A therapeutic agent of paramount importance in acute anticonvulsant therapy
by: Farah Iram, et al.
Published: (2017-01-01)

Development of a stress induced validated UPLC-PDA method for the analysis of Eslicarbazepine acetate
by: Farah Iram, et al.
Published: (2018-02-01)

Efficacy and tolerability of eslicarbazepine acetate as monotherapy in patients of newly diagnosed focal epilepsy
by: S. Saxena, et al.
Published: (2021-04-01)

Eslicarbazepine acetate is porphyrogenic and should be used with caution in patients with the acute hepatic porphyrias
by: Christopher D. Ma, et al.
Published: (2022-09-01)

A review of the efficacy and safety of eslicarbazepine acetate in the management of partial-onset seizures
by: Rodrigo Rocamora
Published: (2015-07-01)

Efficacy and safety of using eslicarbazepine in treating focal epilepsy in clinical practice (based on international Euro-Esli study and personal experience)
by: I. A. Zhidkova, et al.
Published: (2020-11-01)

Psychiatric adverse events in three phase III trials of eslicarbazepine acetate for focal seizures
by: Hamada Altalib, et al.
Published: (2022-12-01)

The pharmacokinetic, safety, and tolerability profiles of eslicarbazepine acetate are comparable between Korean and White subjects
by: Sejung Hwang, et al.
Published: (2022-09-01)

Severe myoclonic epilepsy of infancy: Seizure reduction during adjunctive eslicarbazepine in two cases
by: Sabrina Buoni, et al.
Published: (2015-01-01)

Evaluation of the Effect of Eslicarbazepine Acetate on the Pharmacokinetics of Perampanel in Rats by Isotope-Dilution-UHPLC-MS/MS
by: Liu P, et al.
Published: (2022-11-01)

Adjunctive Treatment With Eslicarbazepine Acetate for Adults and Children With Focal-Onset Epilepsy: A Meta-Analysis
by: Yanqing Fei, et al.
Published: (2022-07-01)

Eslicarbazepine, but Not Lamotrigine or Ranolazine, Shows Anticonvulsant Efficacy in Carbamazepine-Resistant Rats Developed by Window-Pentylenetetrazole Kindling
by: Cecilia Zavala-Tecuapetla, et al.
Published: (2022-05-01)

Antiepileptogenesis after stroke—trials and tribulations: Methodological challenges and recruitment results of a Phase II study with eslicarbazepine acetate
by: Matthias J. Koepp, et al.
Published: (2023-09-01)

Impact of Early Initiation of Eslicarbazepine Acetate on Economic Outcomes Among Patients with Focal Seizure: Results from Retrospective Database Analyses
by: Darshan Mehta, et al.
Published: (2020-09-01)

Identification of metabolic pathways involved in the biotransformation of eslicarbazepine acetate using UPLC-MS/MS, human microsomal enzymes and in silico studies
by: Asif Husain, et al.
Published: (2021-03-01)

Comparative Economic Outcomes in Patients with Focal Seizure Initiating First-Line Eslicarbazepine Acetate Monotherapy versus Generic Antiseizure Drugs
by: Mehta D, et al.
Published: (2021-04-01)

Clinical utility of ulipristal acetate for the treatment of uterine fibroids: current evidence
by: Trefoux Bourdet A, et al.
Published: (2015-03-01)

Clinical utility of apixaban in the prevention and treatment of venous thromboembolism: current evidence
by: Zalpour A, et al.
Published: (2014-11-01)

Effectiveness and Safety/Tolerability of Eslicarbazepine Acetate in Epilepsy Patients Aged ≥ 60 Versus < 60 Years: A Subanalysis from the Euro-Esli Study
by: Charlotte Lawthom, et al.
Published: (2019-05-01)

Clinical utility of brain stimulation modalities following traumatic brain injury: current evidence
by: Li S, et al.
Published: (2015-06-01)

Monitoring And Managing Depression In Adolescents With Epilepsy: Current Perspectives
by: Coppola G, et al.
Published: (2019-09-01)

Lipid profile with eslicarbazepine acetate and carbamazepine monotherapy in adult patients with newly diagnosed focal seizures: analysis of a phase III trial and open-label extension study
by: Eugen Trinka, et al.
Published: (2023-09-01)

Current clinical evidence on pioglitazone pharmacogenomics
by: Marina eKawaguchi-Suzuki, et al.
Published: (2013-11-01)

Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidence
by: Togashi Y, et al.
Published: (2014-07-01)

Reintroducing Fenfluramine as a Treatment for Seizures: Current Knowledge, Recommendations and Gaps in Understanding
by: Dini G, et al.
Published: (2023-09-01)

Identification, synthesis and characterization of an unknown process related impurity in eslicarbazepine acetate active pharmaceutical ingredient by LC/ESIâIT/MS, 1H, 13C and 1Hâ1H COSY NMR
by: Saji Thomas, et al.
Published: (2014-10-01)

Immunonutrition in clinical practice: what is the current evidence?
by: S. D. Heys, et al.

Clinical Utility of β3-Adrenoreceptor Agonists for the Treatment of Overactive Bladder: A Review of the Evidence and Current Recommendations
by: Krhut J, et al.
Published: (2022-04-01)